An observational study in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Actelion (part of Johnson & Johnson) · Observational
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment. Patient data will be collected prospectively for three years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process.
Approximately 200 male and female adult patients with a history of Eisenmenger will be recruited from approximately 50 cardiology practices over a period of 18 months and will be followed up every six months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Participating sites will be asked to maintain a screening log to identify which inclusion or exclusion criteria was not met thus excluding them from the study.
699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
This study's enrollment of 193 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
200 adult patients with Eisenmenger Syndrome recruited from approximately 50 US cardiology practices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
subjects with diagnosis of Eisenmenger Syndrome
Other: Subjects with diagnosis of Eisenmenger Syndrome
1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine 2. Contraception counseling, and recommendations regarding avoidance of pregnancy 3. Documentation and prescription of the specific medications: 1. Oxygen 2. Diuretic 3. ASA, Anticoagulant 4. CCB, BB, ACEI, ARB 5. Iron Supplementation 6. Allopurinol 7. PAH specific therapy
Also known as: management of Eisenmenger Syndrome
Characterization of the clinical course of patients with Eisenmenger Syndrome
The management of Eisenmenger Syndrome patients over the three year registry period will be compared with established national guidelines. In addition, The Minnesota Living with Heart Failure questionnaire (MLHFQ) will be collected.
Time frame: up to 3 years
Characterization of the demographics of patients with Eisenmenger Syndrome
Time frame: baseline (visit 1) thru end of study (3 years)
Identification of clinical predictors of short-term and long-term outcomes of patients with Eisenmenger Syndrome.
Time frame: baseline (visit 1) thru end of study (3 years)
Characterization of patients treated with PAH-specific medications to patients untreated with PAH-specific medications.
Time frame: baseline (visit 1) thru end of study (3 years)
No study locations are listed for this record.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →